With your prenatal genetic screening guidance, they can.
Family planning is a vulnerable time for your patients, and you’re committed to providing the best care possible. Prenatal genetic screening gives you clinically proven insights to help guide them every step of the way.1,2,3
Empower every patient with actionable insights
Every patient deserves accurate results from genetic screens. That’s why our Myriad Genetics’ portfolio uses the latest technology to provide actionable insights for all patients, regardless of BMI and/or ancestry.4,5,6
Share reliable results— the first time
With the lowest failure rates in the industry and the highest-published at-risk couple’s detection rate,* Myriad screening panels deliver results the first time. This means less repeat screening and more time to plan in the rare event your patient’s child is at risk of inheriting genetic conditions.4,6,7
*For the Foresight Carrier Screen Universal Panel.
Trust in 30+ years of genetic innovation
At Myriad, we’re committed to nonstop innovation that serves clinicians and patients on the road to conception and pregnancy. Our decades of industry-leading research and development include expanded carrier screening, best-in-class reliability in cell-free DNA screening with AMPLIFY™ Technology, and more.7,8,9
Get to know the
Prequel Prenatal Screen
The only cell-free DNA (cfDNA) screen available at eight weeks’ gestation10
Designed for patients of all BMIs, the Prequel Prenatal Screen offers key insights about the health of their baby as early as eight weeks into pregnancy.4, 10
Get to know the
Foresight Carrier Screen
The carrier screen with the highest at-risk couple detection rate8
Empower patients of all ethnicities to make informed decisions about family planning by detecting if they’re carriers for rare, serious conditions.7
Become a SneakPeek clinical provider
#1 OBGYN-recommended fetal sex test11
Give your patients the option to find out the sex of their baby as soon as six weeks into pregnancy.12
References:
- Dungan JS, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. 2023;25(2):100336. doi:10.1016/j. gim.2022.11.004.
- Screening for fetal chromosomal abnormalities. Obstetrics & Gynecology. 2020;136(4). doi:10.1097/aog.0000000000004084.
- Committee Opinion No. 690 Summary: Carrier Screening in the Age of Genomic Medicine. 2017. Obstetrics & Gynecology. 129 (3): 595–96.
- Welker NC, et al. High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening. Genetics in Medicine. 2021;23(3):443-450. doi:10.1038/s41436-020-01009-5.
- Deputy NP, et al. Prevalence and Trends in Prepregnancy Normal Weight - 48 States, New York City, and District of Columbia, 2011-2015. MMWR Morb Mortal Wkly Rep. 2018;66(51-52):1402-1407. Published 2018 Jan 5. doi:10.15585/mmwr.mm665152a3.
- Hogan GJ, et al. Validation of an Expanded Carrier Screen that Optimizes Sensitivity via Full-Exon Sequencing and Panel-wide Copy Number Variant Identification. Clinical Chemistry. 2018; doi:10.1373/clinchem.2018.286823.
- Foresight® Residual Risk Table. https://myriad-library.s3.amazonaws.com/mwh/disease-detection-fact-sheet.pdf.
- Hancock S, et al. Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate. Ultrasound Obstet Gynecol. 2020;56(3):422-430. doi:10.1002/uog.21904.
- Muzzey D, et al. Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk. Prenat Diagn. 2020;40(3):333-341. doi:10.1002/pd.5603.
- Dugoff L. Fetal fraction amplification enables accurate prenatal cell-free DNA screening at 8 weeks gestation. Presented at: the Society for Maternal Fetal Medicine 2025 Pregnancy Meeting; January 30, 2025; Denver, CO.
- SneakPeek recommended six to one among 100 OBGYNs, Jan 2024.
- Milot H, et al. Large scale follow-up research study: SneakPeek® Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation. Int J Pregn & Chi Birth. 2020;6(6):165‒168. DOI: 10.15406/ipcb.2020.06.00217.
